Menlo Therapeutics Inc (MNLO) Stock News
NASDAQ:MNLO - Nasdaq -
MNLO Latest News, Press Relases and Analysis
Menlo Therapeutics changes name to Vyne Therapeutics (NASDAQ:MNLO)
Menlo Therapeutics (MNLO) changed its name to Vyne Therapeutics and will trade under the symbol to 'VYNE'; effective trading today."We are excited to launch our new corporate identity as VYNE Therapeutics today, and are honored to be marking this important milestone in our company's history by ringing the Nasdaq closing bell," president & CEO David Domzalski commented.No change in outstanding common shares and stockholders rights.
LifeSci Capital Sticks to Its Buy Rating for Menlo Therapeutics (MNLO)
Analysts Offer Insights on Healthcare Companies: Menlo Therapeutics (NASDAQ: MNLO) and Inmune Bio (NASDAQ: INMB)
Mentions: INMB
Menlo Therapeutics (MNLO) Received its Third Buy in a Row
After Cantor Fitzgerald and H.C. Wainwright gave Menlo Therapeutics (NASDAQ: MNLO) a Buy rating last month, the company received another Buy, this time from Northland Securities. Analyst Tim Chiang maintained a Buy rating on Menlo Therapeutics today and set a price target of $6.00. The company’s shares closed last Wednesday at $2.09. According to TipRanks.com,
Menlo Therapeutics Inc. (MNLO) Reports Q2 Loss, Tops Revenue Estimates
Menlo Therapeutics Inc. (MNLO) delivered earnings and revenue surprises of -476.19% and 472.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
FSLY, WDC among premarket losers
MicroVision (NASDAQ:MVIS) -30% on Q2 earnings.OraSure Technologies (NASDAQ:OSUR) -20% on Q2 earnings.Fastly (NYSE:FSLY) -18% on Q2 earnings.Blue Apron Holdings (NYSE:APRN) -18% on pricing equity offering.Inseego (NASDAQ:INSG) -15% on Q2 earnings.ADMA Biologics (NASDAQ:ADMA) -15% on Q2 earnings.Citius Pharmaceuticals (NASDAQ:CTXR) -15% after announcing "bought deal" offering.Sonos (NASDAQ:SONO) -13% on Q3 earnings.Houghton Mifflin Harcourt (NASDAQ:HMHC) -4% on Q2 earnings.Western Digital (NASDAQ:WDC) -12% on Q4 earnings.Wix.com (NASDAQ:WIX) -11% on Q2 earnings.Aileron Therapeutics (NASDAQ:ALRN) -11% on Q2 earnings.Caladrius Biosciences (NASDAQ:CLBS) -10% after CFO resigns.ADT (NYSE:ADT) -10% on Q2 earnings.MYOS RENS Technology (NASDAQ:MYOS) -9%.TherapeuticsMD (NASDAQ:TXMD) -9% on Q2 earnings.Professional Diversity Network (NASDAQ:IPDN) -9%.3D Systems (NYSE:DDD) -9% on Q2 earnings.Four Seasons Education (Cayman) (NYSE:FEDU) -8%.Infrastructure and Energy Alternatives (NASDAQ:IEA) -8%.MannKind (NASDAQ:MNKD) -8% on Q2 earnings.Transocean (NYSE:RIG) -8% after executing a private exchange agreement relating to the 0.5% Exchangeable Bonds due 2023.Proteostasis Therapeutics (NASDAQ:PTI) -7%.Menlo Therapeutics (NASDAQ:MNLO) -7% on Q2 earnings.Carnival (NYSE:CCL) -7% on launch of direct offering.WISeKey International Holding (NASDAQ:WKEY) -7%.Camping World Holdings (NYSE:CWH) -7% on Q2 earnings.
110 Biggest Movers From Yesterday
Gainers ADiTx Therapeutics, Inc. (NASDAQ: ADTX) shares climbed 93.4% to close at $7.60 on Thursday after the company reported introduction of AditxtScore for COVID-19 and...
Menlo Therapeutics EPS misses by $0.93, beats on revenue (NASDAQ:MNLO)
Menlo Therapeutics (NASDAQ:MNLO): Q2 GAAP EPS of -$1.21 misses by $0.93.Revenue of $11.7M beats by $9.66M.Shares -1.9% PM.Press Release
Why Menlo Therapeutics Is Trading Lower Today
Menlo Therapeutics Inc (NASDAQ: MNLO) shares are trading lower on Friday, after the company reported a common stock offering of 27.05 million shares at $1.85 per share. Menlo...
Menlo Therapeutics (MNLO) Received its Third Buy in a Row
After Cantor Fitzgerald and H.C. Wainwright gave Menlo Therapeutics (NASDAQ: MNLO) a Buy rating last month, the company received another Buy, this time
Why Menlo Therapeutics Stock Sank Today
The pricing of the biotech's stock offering weighed on shares.
Healthcare - Top 5 Gainers / Losers
Gainers: Sientra (NASDAQ:SIEN) +25%. Tetraphase Pharmaceuticals (NASDAQ:TTPH) +20%. Immunic (NASDAQ:IMUX) +17%. China Jo-Jo Drugstores (NASDAQ:CJJD) +15%. Tenet Healthcare (NYSE:THC) +15%.Losers: Tita
Menlo Therapeutics drops 17% after pricing equity offering (NASDAQ:MNLO)
Menlo Therapeutics (NASDAQ:MNLO) has priced its public offering of ~27.1M common shares at $1.85/share, for expected gross proceeds of $50,042,500.Underwriters' over-allotment is an additional 4,057,
Menlo Therapeutics readies equity offering (NASDAQ:MNLO)
Menlo Therapeutics (NASDAQ:MNLO) initiates a public offering of common stock. Price, volume and terms have yet to be announced.Shares down 10% after hours.
Menlo combo skin foam shows positive action in mid-stage acne study (NASDAQ:MNLO)
Menlo Therapeutics (MNLO -4.4%) announces positive, though mixed, results from a 447-subject Phase 2 clinical trial, Study FX2016-40, evaluating FCD105 (3% minocycline/0.3% adapalene foam) for the tre
Menlo Therapeutics (MNLO) Received its Third Buy in a Row
After H.C. Wainwright and Cantor Fitzgerald gave Menlo Therapeutics (NASDAQ: MNLO) a Buy rating last month, the company received another Buy, this time